{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:09:13Z","timestamp":1793372953283,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"NIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jinf.2024.106130","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T17:09:19Z","timestamp":1709226559000},"page":"106130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0852-627X","authenticated-orcid":false,"given":"Gail","family":"Hayward","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0331-7364","authenticated-orcid":false,"given":"Ly-Mee","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2963-4491","authenticated-orcid":false,"given":"Oghenekome","family":"Gbinigie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4842-9247","authenticated-orcid":false,"given":"Milensu","family":"Shanyinde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6072-1430","authenticated-orcid":false,"given":"Jienchi","family":"Dorward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin R.","family":"Saville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8701-3258","authenticated-orcid":false,"given":"Nicholas","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip H.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas P.B.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahendra G.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver V.","family":"Hecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Detry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8872-3646","authenticated-orcid":false,"given":"Jared","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Latimer-Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7643-572X","authenticated-orcid":false,"given":"Emma","family":"Ogburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7498-1276","authenticated-orcid":false,"given":"Jenna","family":"Grabey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"de Lusignan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FD Richard","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2024.106130_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antivir Res"},{"issue":"11","key":"10.1016\/j.jinf.2024.106130_bib2","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s00011-008-8007-8","article-title":"Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice","volume":"57","author":"Zhang","year":"2008","journal-title":"Inflamm Res"},{"key":"10.1016\/j.jinf.2024.106130_bib3","article-title":"Nonspecific membrane bilayer perturbations by ivermectin underlie SARS-CoV-2 in vitro activity","author":"Eastman","year":"2023","journal-title":"bioRxiv"},{"issue":"5","key":"10.1016\/j.jinf.2024.106130_bib4","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1080\/07391102.2020.1839564","article-title":"Binding mechanism and structural insights into the identified protein target of COVID-19 and importin-\u03b1 with in-vitro effective drug ivermectin","volume":"40","author":"Sen Gupta","year":"2022","journal-title":"J Biomol Struct Dyn"},{"key":"10.1016\/j.jinf.2024.106130_bib5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jclinepi.2021.12.018","article-title":"Bias as a source of inconsistency in ivermectin trials for COVID-19: A systematic review. Ivermectin's suggested benefits are mainly based on potentially biased results","volume":"144","author":"Izcovich","year":"2022","journal-title":"J Clin Epidemiol"},{"issue":"9","key":"10.1016\/j.jinf.2024.106130_bib6","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1007\/s11606-021-06948-6","article-title":"Increase in outpatient ivermectin dispensing in the US during the COVID-19 pandemic: a cross-sectional analysis","volume":"36","author":"Lind","year":"2021","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.jinf.2024.106130_bib7","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/d41586-020-02958-2","article-title":"Latin America\u2019s embrace of an unproven COVID treatment is hindering drug trials Unchecked ivermectin use in the region is making it difficult to test the anti-parasite drug\u2019s effectiveness against the coronavirus","volume":"586","year":"2020","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.jinf.2024.106130_bib8","first-page":"309","article-title":"Interventions in an ambulatory setting to prevent progression to severe disease in patients with covid-19: a systematic review","volume":"56","author":"Murchu","year":"2022","journal-title":"Ann Pharm"},{"issue":"1","key":"10.1016\/j.jinf.2024.106130_bib9","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12985-022-01829-8","article-title":"Ivermectin under scrutiny: a systematic review and meta-analysis of efficacy and possible sources of controversies in COVID-19 patients","volume":"19","author":"Shafiee","year":"2022","journal-title":"Virol J"},{"issue":"6","key":"10.1016\/j.jinf.2024.106130_bib10","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/cid\/ciab591","article-title":"Ivermectin for the treatment of coronavirus disease 2019: a systematic review and meta-analysis of randomized controlled trials","volume":"74","author":"Roman","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.jinf.2024.106130_bib11","article-title":"Ivermectin for preventing and treating COVID-19","volume":"6","author":"Popp","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.jinf.2024.106130_bib12","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1186\/s12879-022-07589-8","article-title":"Systematic review and meta-analysis of ivermectin for treatment of COVID-19: evidence beyond the hype","volume":"22","author":"Marcolino","year":"2022","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jinf.2024.106130_bib13","article-title":"Is ivermectin effective in treating COVID-19?","volume":"13","author":"Yang","year":"2022","journal-title":"Front Pharm"},{"issue":"3","key":"10.1016\/j.jinf.2024.106130_bib14","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.3079","article-title":"Comparison of trials using ivermectin for COVID-19 between regions with high and low prevalence of strongyloidiasis: a meta-analysis","volume":"5","author":"Bitterman","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"18","key":"10.1016\/j.jinf.2024.106130_bib15","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1056\/NEJMoa2115869","article-title":"Effect of early treatment with ivermectin among patients with COVID-19","volume":"386","author":"Reis","year":"2022","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.jinf.2024.106130_bib16","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1001\/jama.2022.18590","article-title":"Effect of ivermectin vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19: a randomized clinical trial","volume":"328","author":"Naggie","year":"2022","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.jinf.2024.106130_bib17","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2201662","article-title":"Randomized trial of metformin, ivermectin, and fluvoxamine for COVID-19","volume":"387","author":"Bramante","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jinf.2024.106130_bib18","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jama.2023.1650","article-title":"Effect of higher-dose ivermectin for 6 days vs placebo on time to sustained recovery in outpatients with COVID-19: a randomized clinical trial","volume":"329","author":"Naggie","year":"2023","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.jinf.2024.106130_bib19","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S1473-3099(23)00299-2","article-title":"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial","volume":"23","author":"Bramante","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.jinf.2024.106130_bib20","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both","volume":"377","author":"Woodcock","year":"2017","journal-title":"N Engl J Med"},{"issue":"10279","key":"10.1016\/j.jinf.2024.106130_bib21","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S0140-6736(21)00461-X","article-title":"Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial","volume":"397","author":"Butler","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jinf.2024.106130_bib22","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/S2213-2600(21)00310-6","article-title":"Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial","volume":"9","author":"Butler","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"10303","key":"10.1016\/j.jinf.2024.106130_bib23","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0140-6736(21)01744-X","article-title":"Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial","volume":"398","author":"Yu","year":"2021","journal-title":"Lancet"},{"issue":"720","key":"10.1016\/j.jinf.2024.106130_bib24","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3399\/BJGP.2022.0083","article-title":"Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial","volume":"72","author":"Dorward","year":"2022","journal-title":"Br J Gen Pr"},{"key":"10.1016\/j.jinf.2024.106130_bib25","doi-asserted-by":"crossref","first-page":"l6228","DOI":"10.1136\/bmj.l6228","article-title":"Fool's gold? Why blinded trials are not always best.","volume":"368","author":"Anand","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.jinf.2024.106130_bib26","doi-asserted-by":"crossref","first-page":"l6802","DOI":"10.1136\/bmj.l6802","article-title":"Impact of blinding on estimated treatment effects in randomised clinical trials: meta-epidemiological study","volume":"368","author":"Moustgaard","year":"2020","journal-title":"BMJ"},{"issue":"10291","key":"10.1016\/j.jinf.2024.106130_bib27","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/S0140-6736(21)00945-4","article-title":"Inclusion and diversity in the PRINCIPLE trial","volume":"397","author":"Patel","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jinf.2024.106130_bib28","series-title":"COVID-19 Rapid Guideline: Managing Symptoms (including at the end of life) in the Community","author":"National Institute for Health and Care Excellence (NICE)","year":"2020"},{"key":"10.1016\/j.jinf.2024.106130_bib29","unstructured":"National Institute for Health and Care Excellence. COVID-19 rapid guideline: Managing COVID-19. 2022. Accessed August 16, 2022. https:\/\/app.magicapp.org\/#\/guideline\/L4Qb5n\/section\/nBMk69."},{"key":"10.1016\/j.jinf.2024.106130_bib30","unstructured":"NHS England 2023. Accessed March 2nd 2024 https:\/\/www.england.nhs.uk\/statistics\/statistical-work-areas\/covid-therapeutics-antivirals-and-neutralising-monoclonal-antibodies\/."},{"key":"10.1016\/j.jinf.2024.106130_bib31","unstructured":"The United Kingdom Government. Coronavirus (COVID-19) in the UK 2020 (updated February 12, 2021) https:\/\/coronavirus.data.gov.uk\/."},{"issue":"6","key":"10.1016\/j.jinf.2024.106130_bib32","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1473-3099(20)30243-7","article-title":"Estimates of the severity of coronavirus disease 2019: a model-based analysis","volume":"20","author":"Verity","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.1016\/j.jinf.2024.106130_bib33","doi-asserted-by":"crossref","first-page":"623","DOI":"10.7326\/M20-4207","article-title":"Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial","volume":"173","author":"Skipper","year":"2020","journal-title":"Ann Intern Med"},{"issue":"19","key":"10.1016\/j.jinf.2024.106130_bib34","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of COVID-19\u2014final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jinf.2024.106130_bib35","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000376585","article-title":"The WHO-5 well-being index: a systematic review of the literature","volume":"84","author":"Topp","year":"2015","journal-title":"Psychother Psychosom"},{"issue":"5","key":"10.1016\/j.jinf.2024.106130_bib36","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1177\/17407745221112013","article-title":"The Bayesian Time Machine: accounting for temporal drift in multi-arm platform trials","volume":"19","author":"Saville","year":"2022","journal-title":"Clin Trials"},{"key":"10.1016\/j.jinf.2024.106130_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10543406.2023.2275765","article-title":"Adaptive platform trials: the impact of common controls on type one error and power","author":"Nguyen","year":"2023","journal-title":"J Biopharm Stat"},{"issue":"8","key":"10.1016\/j.jinf.2024.106130_bib38","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with COVID-19","volume":"384","author":"Recovery Collaborative Group","year":"2021","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.jinf.2024.106130_bib39","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically ill patients with COVID-19","volume":"384","author":"REMAP-CAP Investigators","year":"2021","journal-title":"N Engl J Med"},{"issue":"2-3","key":"10.1016\/j.jinf.2024.106130_bib40","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ctim.2004.07.043","article-title":"Pragmatic clinical trials","volume":"12","author":"MacPherson","year":"2004","journal-title":"Complement Ther Med"},{"key":"10.1016\/j.jinf.2024.106130_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101011","article-title":"Comparing the diagnostic accuracy of point-of-care lateral flow antigen testing for SARS-CoV-2 with RT-PCR in primary care (REAP-2)","volume":"38","author":"Leber","year":"2021","journal-title":"EClinicalMedicine"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445324000641?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445324000641?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T15:43:29Z","timestamp":1716824609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445324000641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0163445324000641"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2024.106130","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2024.106130","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association.","name":"copyright","label":"Copyright"}],"article-number":"106130"}}